Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial

Ann Oncol. 2018 Dec 1;29(12):2393-2395. doi: 10.1093/annonc/mdy451.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acneiform Eruptions / chemically induced
  • Acneiform Eruptions / diagnosis
  • Acneiform Eruptions / drug therapy*
  • Acneiform Eruptions / epidemiology
  • Administration, Cutaneous
  • Antineoplastic Agents, Immunological / adverse effects*
  • Cetuximab / adverse effects*
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / pathology
  • Drug Eruptions / diagnosis
  • Drug Eruptions / drug therapy*
  • Drug Eruptions / epidemiology
  • Drug Eruptions / etiology
  • ErbB Receptors / antagonists & inhibitors
  • Female
  • Humans
  • Incidence
  • Male
  • Severity of Illness Index
  • Skin Cream / administration & dosage
  • Treatment Outcome
  • Vitamin K 1 / administration & dosage*

Substances

  • Antineoplastic Agents, Immunological
  • Vitamin K 1
  • EGFR protein, human
  • ErbB Receptors
  • Cetuximab